STEAP1: a promising target in prostate cancer therapy.
The unmet therapeutic need in prostate cancer (PCa), a disease that remains largely incurable after metastasis, underscores the urgency for new treatments.
APA
Singh R, Kyte JA (2025). STEAP1: a promising target in prostate cancer therapy.. Trends in cancer, 11(8), 722-725. https://doi.org/10.1016/j.trecan.2025.05.007
MLA
Singh R, et al.. "STEAP1: a promising target in prostate cancer therapy.." Trends in cancer, vol. 11, no. 8, 2025, pp. 722-725.
PMID
40527692
Abstract
The unmet therapeutic need in prostate cancer (PCa), a disease that remains largely incurable after metastasis, underscores the urgency for new treatments. STEAP1 (six transmembrane epithelial antigen of prostate 1) is a cell surface protein highly expressed in >85% prostate tumors but shows little to no presence in normal tissues, making it a promising candidate for targeted therapy. Here, we summarize and discuss recent findings that underscore the promising role of STEAP1 in PCa therapy.
MeSH Terms
Humans; Male; Prostatic Neoplasms; Molecular Targeted Therapy; Antigens, Neoplasm; Oxidoreductases; Gene Expression Regulation, Neoplastic; Biomarkers, Tumor; Animals
같은 제1저자의 인용 많은 논문 (5)
- Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity.
- Canniprene B, a new prenylated dihydrostilbene with cytotoxic activities from the leaves of .
- Impact of Visceral Fat on Perioperative Outcome of Patients Undergoing Laparoscopic Surgery for Colorectal Cancer: Prospective Study.
- Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis.
- Study of Incidence and Location of Nasal Foramen in Nasal Bone of Adult Dry Skulls.